Skip to main content
Equibles
AARD logo

AARD · Aardvark Therapeutics, Inc.

Track AARD — free

Use AARD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AARD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.13 +0.12 (+2.40%) At close · Sep 11
Rebalance outlook locked
Market Cap
$112.27M
Shares
21.88M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$5.13 Open$5.11 Day$4.98–5.54 52W close$3.48–17.41 Avg vol 30d135K Short int510K · 2.3% float · 3.8d Short vol39% DataFeb 2025–Sep 2026 Filing10-Q · Aug 11

Up next

Latest filing: 10-Q
filed Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$69.89M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$73.87M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.7%
Year over year · more shares
Price change (1Y)
-34.1%
Trailing year
Short interest
2.3%
Latest settlement · 3.8 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Neutral Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −35%
below
Price vs 50-day avg −19%
below
RSI (14) 40
neutral
MACD trend Negative
52-week position 12%
near low
Momentum
relative strength
Neutral
1-month return −20%
trailing
6-month return +26%
trailing
YTD return −61%
this year
Relative strength +8%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $6 › 200d $8 — 200d above 50d
Institutional flow Distributing
-11% holders QoQ · +17 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.33% of float · ▼ -16.7% MoM · 3.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
71 holders — mid 1-yr range
Squeeze score 36
low risk · 0–100
Fundamentals
Fair
EPS growth +43%
Y/Y
Free cash flow $-54.3M
Quant / Vol
risk profile
Very High
Volatility 128%
annualized · 1-yr
Max drawdown −80%
past year
ATR 14.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−35% Bearish
Price vs 50-day avg
−19% Bearish
RSI (14)
40 Neutral
MACD trend
Negative Bearish
52-week position
12% Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $6 › 200d $8 — 200d above 50d
Institutional flow Distributing
-11% holders QoQ · +17 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.33% of float · ▼ -16.7% MoM · 3.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
71 holders — mid 1-yr range
Price context
position in its 52-week range
Range low $3 Now $5 · 12% Range high $17
vs 200-day avg -35% vs 50-day avg -19%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AARD
Aardvark Therapeutics, Inc.
this stock
$112.27M -60.9% — — 2.3%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.22B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
71
% held
43.5%
Net QoQ
-744.7K sh
Top holder
Decheng Capital LLC
Held Float
View
Held by Funds
Fund positions
42
View
Short & Settlement
Short Interest Falling
Shares short
509.9K
Days to cover
3.8d
Change
-101.9K sh
View
Short Volume
Short vol %
39%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
45
Value
$288
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
43.1%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-57.6M
EPS diluted
$-2.93
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 17, 2026
This year
15
View
Proposed Sales
Value
$169.9K
Shares
33.9K
Filed
Sep 11, 2026
View
Exempt Offerings
Offering
$85.0M
Filed
May 15, 2024
View

Performance

5D 20D 120D MTD YTD
AARD -10.5% -20.0% +26.0% -15.9% -60.9%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -9.3% -18.2% +8.2% -15.5% -73.0%
Key facts CIK 1774857 CUSIP 002942100 13F (30d) 25 filings 25 filers Visit website Investor relations